Single nucleotide polymorphisms in glioma: from susceptibility loci to pharmacogenomic biomarkers
Gliomas are among the deadliest primary brain tumors, with glioblastoma (GB) carrying a median overall survival of less than 15 months despite surgery, radiotherapy, and chemotherapy. Although somatic alterations in isocitrate dehydrogenase ( IDH1/2 ), the TERT promoter, and 1p/19q chromosomal codeletion now define the 2021 WHO Classification of CNS Tumors, single nucleotide polymorphisms (SNPs) form a distinct biological layer that clinical practice has so far largely ignored. Genome-wide association studies (GWAS) have now confirmed 26 risk loci for glioma, collectively accounting for approximately 27% of the familial risk of GB and 37% of the familial risk of non-GB tumors. This review covers the full landscape of glioma-associated SNPs across all WHO grades and molecular subtypes, examines gene–environment interactions and pharmacogenomic implications, and discusses how germline SNP genotypes serve as an analytical reference for cerebrospinal fluid (CSF) liquid biopsy, in which tumor-derived somatic alterations are detected and quantified. We also address key gaps: the near-exclusive use of European-ancestry cohorts in GWAS, the lack of functional validation for most risk variants, and the path toward polygenic risk score (PRS) in neuro-oncology. Combining multi-omic data with AI is the most direct path to making SNP panels clinically useful.
Authors
- Н. В. Губанова (ORCID: https://orcid.org/0000-0003-2940-3287)
- Григорьева Эльвира Витальевна (ORCID: https://orcid.org/0000-0003-2457-9179)
Institutions
- Sirius University of Science and Technology (RU)
- Institute of Molecular Biology and Biophysics (RU)
Publication Details
- Journal
- Frontiers in Molecular Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fmmed.2026.2013984
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00